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INTRODUCTION
This chapter makes treatment recommendations for children
aged 1 to 18 years with nephrotic syndrome, who respond to
corticosteroid therapy by achieving complete remission
(SSNS). The cost implications for global application of this
guideline are addressed in Chapter 2. This chapter does not
apply to children under 1 year of age in whom nephrotic
syndrome is often associated with gene mutations and with
histologies other than MCD.
3.1: Treatment of the initial episode of SSNS
3.1.1: We recommend that corticosteroid therapy
(prednisone or prednisolone)* be given for at
least 12 weeks. (1B)
3.1.1.1: We recommend that oral prednisone
be administered as a single daily
dose (1B) starting at 60 mg/m2/d or
2 mg/kg/d to a maximum 60 mg/d. (1D)
3.1.1.2: We recommend that daily oral pre-
dnisone be given for 4–6 weeks (1C)
followed by alternate-day medication
as a single daily dose starting at
40 mg/m2 or 1.5 mg/kg (maximum
40 mg on alternate days) (1D) and
continued for 2–5 months with taper-
ing of the dose. (1B)
*Prednisone and prednisolone are equivalent, used in the same
dosage, and have both been used in RCTs depending on the country
of origin. All later references to prednisone in this chapter refer to
prednisone or prednisolone. All later references to oral corticoster-
oids refer to prednisone or prednisolone.
BACKGROUND
Nephrotic syndrome affects 1–3 per 100,000 children below
16 years of age.14 Eighty percent of children respond to
corticosteroid therapy.14 A kidney biopsy diagnosis is not
required routinely at presentation because the International
Study of Kidney Disease in Children (ISKDC) demonstrated
that, while 93% of children with MCD responded to
corticosteroids, 25–50% of children with mesangial prolif-
erative glomerulonephritis (MPGN) or FSGS also responded
to corticosteroids.15 The majority of children who relapse
continue to respond completely to corticosteroids through-
out their subsequent course, and the long-term prognosis,
including maintenance of normal kidney function, is
good.16–18 In contrast, without treatment, nephrotic syn-
drome in children is associated with high risk of death,
particularly from bacterial infection. Before the use of
corticosteroids and antibiotics, 40% of children died, with
half of these deaths being from infection.19 A recent study
reports only one death (0.7%) associated with nephrotic
syndrome among 138 children with SSNS presenting between
1970 and 2003.20
The definitions used for nephrotic syndrome, complete
remission, initial responder, initial and late steroid non-
responders (steroid resistance), infrequent relapses, frequent
relapses and steroid dependence are listed in Table 1. The
likelihood of initial corticosteroid unresponsiveness is
increased with increasing age at presentation,14 in African
and African-American children,21 and in children with
kidney pathologies other than MCD.15 The likelihood of late
resistance to corticosteroids is associated with a shorter
interval to the first relapse, and relapsing during the initial
course of corticosteroid therapy.22
RATIONALE
K There is moderate-quality evidence that administering
prednisone for three months reduces the risk of relapse in
children with the first episode of SSNS, with an increase
in benefit seen with up to 6 months of treatment.
K There is moderate-quality evidence that corticosteroid
therapy should be given as a single daily dose for at least
4 weeks, followed by alternate-day therapy for 2–5 months.
K The initial dose regimen of corticosteroid therapy is
based on recommendations from the ISKDC, and has not
been defined in RCTs.
Corticosteroid Use in the First Episode of SSNS in Children
With corticosteroid therapy, 80–90% of patients with child-
hood nephrotic syndrome achieve complete remission.14,17
However, 80–90% of these children have one or more
relapses17,18 following the 2-month steroid regimen proposed
by the ISKDC23 and adapted by Arbeitsgemeinschaft fu¨r
Pa¨diatrische Nephrologie.24 Therefore, RCTs have evaluated
the benefits of increased duration of therapy for the initial
episode of SSNS. A meta-analysis25 of six RCTs (422
children) demonstrated that the risk of relapse at 12–24
months was reduced by 30% (risk ratio of relapse 0.70; 95%
confidence intervals [CI] 0.58–0.84) with 3 months or more
of corticosteroid therapy compared to 2 months. There was
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an inverse linear relationship between duration of treatment
and risk of relapse seen when prednisone was given for up
to 6 months (risk ratio¼ 1.26 –0.112 duration; r2¼ 0.56,
P¼ 0.03).25 Also a meta-analysis25 of four RCTs (382
children) identified that treatment for 6 months significantly
reduced the risk of relapse at 12–24 months compared to
3 months (RR 0.57; 95% CI 0.45–0.71). No significant
differences in the incidence of adverse effects between
treatment groups were demonstrated. However, individual
trials were not designed specifically to study harm, and so
were underpowered for the detection of side-effects of
corticosteroids.25
There are no RCTs examining different initial doses of
corticosteroid for the first episode of childhood nephrotic
syndrome. A dose of prednisone 60 mg/m2/d was recom-
mended empirically by the ISKDC in 1979; this is roughly
equivalent to 2 mg/kg. Although theoretical studies indicate
that dosing for body weight results in a lower total dose
compared to dosing for surface area, there are no data on
whether this is of clinical relevance, so either method of
calculating prednisone dose may be utilized.26 Two RCTs have
demonstrated that the mean time to remission did not differ
significantly when daily corticosteroid therapy was given as a
single daily dose compared to divided doses (weighted mean
difference 0.04 days; 95% CI 0.98–1.06).25
The majority (94%) of children respond to corticosteroids
within 4 weeks of daily prednisone therapy.27 To reduce the
risk of relapse, prednisone should be given daily for at least 4
weeks in the initial episode of nephrotic syndrome. In an RCT,
the risk of relapse was significantly higher at 6 months and 12
months when prednisone was given for 1 month compared to
2 months (RR 1.46; 95% CI 1.01–2.12 at 12 months).28
Prednisone should be given on alternate days after 4 weeks of
daily treatment rather than on 3 consecutive days out of 7 days,
based on an RCT that showed the former had a lower risk of
relapse.29 Alternate-day (rather than daily) prednisone is
suggested to maintain remission, because linear growth is less
affected.30 Although widely used particularly in France,31 there
is no evidence to support the administration of high-dose i.v.
methylprednisolone to a child with nephrotic syndrome, who
has not achieved remission after 4 weeks of daily cortico-
steroids, before labeling that child as steroid-resistant.
3.2: Treatment of relapsing SSNS with corticosteroids
3.2.1: Corticosteroid therapy for children with in-
frequent relapses of SSNS:
3.2.1.1: We suggest that infrequent relapses
of SSNS in children be treated
with a single-daily dose of prednisone
60 mg/m2 or 2 mg/kg (maximum of
60 mg/d) until the child has been in
complete remission for at least
3 days. (2D)
3.2.1.2: We suggest that, after achieving com-
plete remission, children be given
prednisone as a single dose on alternate
days (40 mg/m2 per dose or 1.5 mg/kg
per dose: maximum 40 mg on alternate
days) for at least 4 weeks. (2C)
3.2.2: Corticosteroid therapy for frequently relaps-
ing (FR) and steroid-dependent (SD) SSNS:
3.2.2.1: We suggest that relapses in children
with FR or SD SSNS be treated with
daily prednisone until the child has
been in remission for at least 3 days,
followed by alternate-day prednisone
for at least 3 months. (2C)
3.2.2.2: We suggest that prednisone be given
on alternate days in the lowest dose to
maintain remission without major
adverse effects in children with FR
and SD SSNS. (2D)
3.2.2.3: We suggest that daily prednisone at
the lowest dose be given to maintain
remission without major adverse ef-
fects in children with SD SSNS where
alternate-day prednisone therapy is
not effective. (2D)
Table 1 | Definitions of nephrotic syndrome in children
Classification Definition
Nephrotic syndrome Edema, uPCR X2000mg/g (X200mg/mmol), or X300mg/dl, or 3+ protein on urine dipstick, hypoalbuminaemia
p2.5 g/dl (p25 g/l)
Complete remission uPCR o200mg/g (o20mg/mmol) or o1+ of protein on urine dipstick for 3 consecutive days
Partial remission Proteinuria reduction of 50% or greater from the presenting value and absolute uPCR between 200 and 2000mg/g
(20–200mg/mmol)
No remission Failure to reduce urine protein excretion by 50% from baseline or persistent excretion uPCR42000mg/g (4200mg/mmol)
Initial responder Attainment of complete remission within initial 4 weeks of corticosteroid therapy
Initial nonresponder/
steroid resistance
Failure to achieve complete remission after 8 weeks of corticosteroid therapy
Relapse uPCR X2000mg/g (X200mg/mmol) or X3+ protein on urine dipstick for 3 consecutive days
Infrequent relapse One relapse within 6 months of initial response, or one to three relapses in any 12-month period
Frequent relapse Two or more relapses within 6 months of initial response, or four or more relapses in any 12-month period
Steroid dependence Two consecutive relapses during corticosteroid therapy, or within 14 days of ceasing therapy
Late nonresponder Persistent proteinuria during 4 or more weeks of corticosteroids following one or more remissions
uPCR, urine protein:creatinine ratio.
164 Kidney International Supplements (2012) 2, 163–171
chapte r 3
3.2.2.4: We suggest that daily prednisone be
given during episodes of upper res-
piratory tract and other infections to
reduce the risk for relapse in children
with FR and SD SSNS already on
alternate-day prednisone. (2C)
BACKGROUND
Children with nephrotic syndrome who respond to cortico-
steroids have an 80–90% chance of having one or more
relapses.17,18 Half of those that relapse have infrequent
relapses and can be managed with short courses of
prednisone. The remaining children have FR or SD SSNS.17,18
The risks of a child developing frequent relapses or becoming
steroid-dependent are increased with shorter time to first
relapse,32 the number of relapses in the first 6 months after
initial treatment,15,18 younger age at the initial episode,33,34
in boys,34 prolonged time to first remission,31,35 infection at
first relapse,32 and hematuria in first episode.35 The most
consistent indicator for a frequently relapsing course is early
relapse after initial treatment. Studies have not assessed
whether the other factors are independent risk factors for
predicting frequent relapses or steroid dependence. Children
with FR or SD SSNS, and children whose first episode of
SSNS occurred at a young age, have a longer duration of
relapsing or SD nephrotic syndrome compared to children
with infrequent relapses or older age of onset.16,33 Corticos-
teroids are needed to achieve remission, and low doses given
on alternate days may maintain remission in patients with FR
SSNS without recourse to corticosteroid-sparing agents. Low-
dose daily or alternate-day corticosteroids may still be
required to maintain remission in SD SSNS, despite receiving
corticosteroid-sparing agents.
RATIONALE
K In children with infrequent relapses of SSNS, corticoster-
oid therapy regimens are based on empirical recommen-
dations from the ISKDC and an RCT in children with FR
SSNS.
K In children with FR and SD SSNS, there is low-quality
evidence that increasing the duration of corticosteroid
therapy increases the duration of remission.
K In children with SD SSNS, there is low-quality evidence
that changing children from alternate-day to daily
corticosteroids at onset of upper respiratory infections
reduced the risk of relapse.
K In children with FR and SD SSNS, there is very
low–quality evidence that low-dose alternate-day or daily
corticosteroid therapy reduces the risk of relapse.
Corticosteroid Use in Relapses in Children with Infrequent
Relapses of SSNS
There are no RCTs examining relapse regimens with
corticosteroids in infrequently relapsing SSNS. In children
with frequently relapsing SSNS, the ISKDC demonstrated
that the number of relapses in the 7 months after treatment
did not differ significantly between children treated with
8 weeks of daily prednisone compared to daily prednisone
till remission followed by 4 weeks of prednisone given on
3 consecutive days out of 7 days (further relapse by 9 months
RR 1.07; 95% CI 0.77–1.50).25 Based on these data we suggest
that children with infrequently relapsing SSNS should receive
daily corticosteroids only until remission followed by four
weeks of alternate day prednisone.
Corticosteroid Therapy in Frequently Relapsing (FR) and
Steroid-Dependent (SD) SSNS in Children
Approximately 40% of children with SSNS have FR or SD
SSNS. A single RCT in children with relapsing nephrotic
syndrome demonstrated that the risk of relapse at 12 and 24
months was significantly reduced with prednisone treatment
for 7 months compared to 2 months of therapy.25 These data,
and the data on prednisone duration in the initial episode of
SSNS, suggest that it is reasonable to treat a child with FR or
SD SSNS with longer corticosteroid regimens than those
suggested for children who relapse infrequently. Three RCTs
have demonstrated that daily prednisone dose during upper
respiratory tract and other infections reduced the risk for
relapse in children with SD SSNS.25,36,37
To maintain remission in children with SD SSNS,
prednisone may be given on alternate days in the lowest
dose possible to maintain remission. An observational study
demonstrated that low-dose alternate-day prednisone (mean
dose 0.48 mg/kg on alternate days) reduced the risk of relapse
in FR SSNS compared to historical controls.38 Guidelines
from the British Association of Paediatric Nephrology
recommend that children with SD SSNS receive 0.1–0.5 mg/
kg on alternate days for at least 3–6 months before tapering.39
Guidelines from the Indian Paediatric Nephrology Group
recommend that the prednisone dose be tapered to
0.5–0.7 mg/kg on alternate days or lower, and continued for
9–18 months with careful monitoring of corticosteroid
toxicity.40 A nonrandomized comparator study indicated
that low-dose daily prednisone (0.25 mg/kg) was more
effective in maintaining remission compared to historical
controls not treated with low-dose prednisone with a
reduction in relapse rate from 2.25 per patient per year to
0.5 per patient per year.41
3.3: Treatment of FR and SD SSNS with corticosteroid-
sparing agents
3.3.1: We recommend that corticosteroid-sparing
agents be prescribed for children with FR
SSNS and SD SSNS, who develop steroid-
related adverse effects. (1B)
3.3.2: We recommend that alkylating agents, cyclo-
phosphamide or chlorambucil, be given as
corticosteroid-sparing agents for FR SSNS.
(1B) We suggest that alkylating agents, cyclo-
phosphamide or chlorambucil, be given as
corticosteroid-sparing agents for SD SSNS.
(2C)
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3.3.2.1: We suggest that cyclophosphamide
(2 mg/kg/d) be given for 8–12 weeks
(maximum cumulative dose 168 mg/kg).
(2C)
3.3.2.2: We suggest that cyclophosphamide not
be started until the child has achie-
ved remission with corticosteroids.
(2D)
3.3.2.3: We suggest that chlorambucil (0.1–
0.2 mg/kg/d) may be given for 8 weeks
(maximum cumulative dose 11.2 mg/kg)
as an alternative to cyclophosphamide.
(2C)
3.3.2.4: We suggest that second courses of
alkylating agents not be given. (2D)
3.3.3: We recommend that levamisole be given as a
corticosteroid-sparing agent. (1B)
3.3.3.1: We suggest that levamisole be given at
a dose of 2.5 mg/kg on alternate days (2B) for
at least 12 months (2C) as most children will
relapse when levamisole is stopped.
3.3.4: We recommend that the calcineurin inhibitors
cyclosporine or tacrolimus be given as corti-
costeroid-sparing agents. (1C)
3.3.4.1: We suggest that cyclosporine be admin-
istered at a dose of 4–5 mg/kg/d (starting
dose) in two divided doses. (2C)
3.3.4.2: We suggest that tacrolimus 0.1 mg/kg/d
(starting dose) given in two divided
doses be used instead of cyclosporine
when the cosmetic side-effects of
cyclosporine are unacceptable. (2D)
3.3.4.3: Monitor CNI levels during therapy to
limit toxicity. (Not Graded)
3.3.4.4: We suggest that CNIs be given for at
least 12 months, as most children will
relapse when CNIs are stopped. (2C)
3.3.5: We suggest that MMF be given as a cortico-
steroid-sparing agent. (2C)
3.3.5.1: We suggest that MMF (starting dose
1200 mg/m2/d) be given in two divided
doses for at least 12 months, as most
children will relapse when MMF is
stopped. (2C)
3.3.6: We suggest that rituximab be considered
only in children with SD SSNS who have
continuing frequent relapses despite optimal
combinations of prednisone and cortico-
steroid-sparing agents, and/or who have
serious adverse effects of therapy. (2C)
3.3.7: We suggest that mizoribine not be used as a
corticosteroid-sparing agent in FR and SD
SSNS. (2C)
3.3.8: We recommend that azathioprine not be used
as a corticosteroid-sparing agent in FR and SD
SSNS. (1B)
BACKGROUND
About half of the children with SSNS who relapse will have
FR or SD SSNS.17,18 The long-term prognosis for most
children with SSNS is for complete resolution of their disease
over time and maintenance of normal kidney function.
Therefore limiting the long-term adverse effects of treatment
is an important objective. Children with FR or SD SSNS
require prolonged corticosteroid therapy, which is associated
with significant adverse effects. including impaired linear
growth, behavioral changes, obesity, Cushing’s syndrome,
hypertension, ophthalmological disorders, impaired glucose
tolerance, and reduced bone mineral density. Adverse effects
may persist into adult life in young people, who continue to
relapse after puberty.42 To reduce the risk of corticosteroid-
related adverse effects, children with FR or SD SSNS may
require other agents, including alkylating agents (cyclopho-
sphamide, chlorambucil) and CNI (cyclosporine, tacroli-
mus). Adverse effects of these agents include increased risk of
infection and reduced fertility (alkylating agents)42,43 and
kidney dysfunction and hypertension (CNI).44 CNIs and
MMF are much more expensive than the other agents, and
this may limit access to them in many countries.
RATIONALE
In children with FR and SD SSNS:
K There is moderate-quality evidence to support the use of
alkylating agents (cyclophosphamide, chlorambucil),
levamisole, and CNI (cyclosporine, tacrolimus).
K There is low-quality evidence to support the use of
mycophenolate mofetil (MMF).
K There is very low–quality evidence to support the efficacy
of rituximab.
K There is moderate-quality evidence to demonstrate that
mizoribine and azathioprine are not effective.
Children with FR or SD SSNS often continue to relapse
into adolescence or adulthood, and require prednisone in
variable doses for long periods of time to achieve and
maintain remission. Patients successfully treated with corti-
costeroid-sparing therapy have improved growth rates,
reduced body mass index, reduction of Cushingoid features,
and improvement in other corticosteroid-related adverse
effects.45–48 In all cases when contemplating corticosteroid-
sparing therapy, the adverse effects of such therapy must be
assessed against the benefits, in terms of reducing both the
relapse rate and adverse effects of corticosteroids.
Fourteen RCTs in children have compared cyclopho-
sphamide (three trials), chlorambucil (two trials), levamisole
(six trials), mizoribine (one trial), and azathioprine (two
trials) to placebo, no specific treatment, or prednisone in
children with FR and/or SD SSNS. Trials either did not
differentiate between FR and SD SSNS, or included only SD
SSNS patients. Cyclophosphamide, chlorambucil, and leva-
misole reduced the risk of relapse during short term follow
up (6–12 months) by more than 50% (Table 2). Two RCTs
demonstrated no significant differences in the risk of relapse
166 Kidney International Supplements (2012) 2, 163–171
chapte r 3
between cyclosporine and cyclophosphamide, or between
cyclosporine and chlorambucil during cyclosporine treat-
ment. RCTs have identified no significant differences in the
risk for relapse between levamisole and i.v. cyclophos-
phamide, and between oral cyclophosphamide and oral
chlorambucil.49
Alkylating Agents
Alkylating agents (cyclophosphamide, chlorambucil) may
result in prolonged remission off all therapy, though they
may have significant adverse effects. In RCTs with 6–12
months of follow-up, alkylating agents reduced the risk of
relapse compared to prednisone, placebo, or no specific
treatment by about 65% (RR 0.34; 95% CI 0.18–0.63)49
(Table 2). In a systematic review of observational studies and
RCTs, alkylating agents in FR SSNS resulted in remission
rates of 72% after 2 years but sustained in only 36% after
5 years. These agents were less effective in SD SSNS with
remission rates of 40% and 24% after 2 and 5 years,
respectively.43 Patients younger than 3 years at onset of
SSNS50 and those commencing cyclophosphamide before 3.8
years51 were less likely to achieve long-term remission with
cyclophosphamide, while children aged over 7.5 years were
more likely to achieve long-term remission.51 Eight weeks of
cyclophosphamide therapy was significantly more effective in
reducing the risk for relapse compared to 2 weeks (Table 3).
In SD SSNS patients, there was no significant difference in
the risk of relapse between 8 and 12 weeks of cyclophos-
phamide therapy in one RCT (Table 3). However, the
Arbeitsgemeinschaft fu¨r Pa¨diatrische Nephrologie concluded
that 12 weeks of cyclophosphamide was more effective
compared to historical controls treated for 8 weeks.52
Cyclophosphamide is associated with hemorrhagic cystitis
but this rarely occurs at the doses used. Nevertheless, where
possible, cyclophosphamide should be administered when
the child is in remission, with a good urine output, and can
receive a high fluid intake. The i.v. route may be considered
where nonadherence to therapy is likely. Two RCTs found no
significant difference in the risk of relapse between oral and
i.v. cyclophosphamide at 12–24 months follow-up. However,
at 6 months, significantly more children treated with
monthly pulses of i.v. cyclophosphamide for 6 months were
in remission, compared to oral treatment for 8–12 weeks
(Table 3; Online Suppl Tables 1–3). Studies have demon-
strated the efficacy of chlorambucil at doses of 0.1–0.2 mg/kg/
d given for 8 weeks (cumulative dose 11.2 mg/kg) (Table 2).
Higher doses did not increase efficacy and resulted in
increased risks, particularly of hematological and infectious
adverse effects.53
It is suggested that second courses of alkylating agents not
be given. Gonadal toxicity with alkylating agents is well
documented, with males more affected than females. There is
a dose-dependent relationship between the total dose of
cyclophosphamide and probability of sperm counts below
106/ml. A ‘‘safe’’ dose of cyclophosphamide remains unclear,
but a maximum cumulative dose of 168 mg/kg (2 mg/kg/d
for 12 weeks) in boys is below the total dose (4200–300 mg/
kg) at which azoospermia has generally been reported.43,54
There are fewer data available on chlorambucil, but studies in
patients treated for lymphoma found that azoospermia was
associated with total doses of 10–17 mg/kg, suggesting that
the margin between efficacy and toxicity is narrow for
chlorambucil.55 Studies have reported a higher risk of
malignancy following chlorambucil use compared to cyclo-
phosphamide.43
Levamisole
Five of six RCTs have demonstrated a significant reduction
in the risk for relapse during levamisole treatment com-
pared to prednisone, placebo, or no specific treatment49
(Table 2). In four of these five RCTs that involved children
with FR or SD SSNS, levamisole was given at a dose of
2.5 mg/kg on alternate days. In the sixth trial, a smaller
dose (2.5 mg/kg of levamisole on 2 consecutive days per
week) did not reduce the risk of relapse compared to
placebo.56 Most children relapse when levamisole was dis-
continued. Observational studies have documented a more
prolonged reduction in relapse frequency when it is used for
12–24 months.57–59 Adverse effects of levamisole are un-
common and minor, with mild leucopenia and gastrointest-
Table 2 |Meta-analyses of RCTs of corticosteroid-sparing agents in children with FR or SD SSNS
Agent
N of
RCTs
N of
patients
Risk ratio of relapse
(95% CI)
Time of outcome
(months)
Relative risk
reduction
Cyclophosphamidea 3 102 0.44 (0.26,0.73) 6–12 56%
Chlorambucilb 2 32 0.13 (0.03,0.57) 12 87%
Levamisolec,d 5 269 0.43 (0.27,0.68) 4–12 57%
Mizoribinee 1 197 Relapse rate ratiof 0.81 (0.61, 1.05) 18 Not significant
Azathioprineg 2 60 0.90 (0.59,1.38) 6 Not significant
CI, confidence interval; FR, frequently relapsing; RCT, randomized controlled trial; SD, steroid-dependent; SSNS, steroid-sensitive nephrotic syndrome.
aCyclophosphamide and prednisone vs. prednisone.
bChlorambucil and prednisone vs. prednisone, or vs. placebo and prednisone.
cLevamisole and prednisone vs. placebo and prednisone, levamisole and prednisone vs. prednisone, levamisole vs. prednisone, Levamisole vs. no specific therapy.
dOne trial using much lower dose of levamisole was excluded (see text).
eMizoribine and prednisone vs. placebo and prednisone.
fRelapse risk ratio¼ [Total number of relapsesCobservation period in treatment group]C[Total number of relapsesCobservation period in control group].
gAzathioprine and prednisone vs. placebo and prednisone, azathioprine and prednisone vs. prednisone.
Data from Hodson et al.49
Kidney International Supplements (2012) 2, 163–171 167
chapte r 3
inal upsets described. Rare cases of cutaneous vasculitis have
been described with levamisole therapy.60 Levamisole is
unavailable in many countries.
CNIs
Two RCTs have demonstrated no significant differences in the
risk of relapse between cyclosporine during treatment and
cyclophosphamide or chlorambucil during treatment.61,62
However, cyclosporine has a higher relapse rate compared to
alkylating agents when assessed at 12–24 months after
treatment. An RCT from Japan reported that 50% of 49
children treated with cyclosporine relapsed compared to 70%
of 59 children treated with placebo during the 24 weeks of
therapy.63 In observational studies, cyclosporine maintains
remission in 60–90% of children with SD SSNS, who had
relapsed after alkylating-agent therapy.64–66 However, in
children with SD SSNS due to biopsy-proven MCD, only
40% remained in remission after 2 years of therapy and all
relapsed within a median of 26 days when cyclosporine
was discontinued.65 Most studies have used cyclosporine
at 3–6 mg/kg/d in two divided doses targeting 12-hour
trough levels of 80–150 ng/ml [67–125 nmol/l] with main-
tenance of lower levels after a child has been in stable
remission for 3–6 months, aiming to minimize cyclosporine
nephrotoxicity. In an RCT the sustained remission rate was
significantly higher in children maintaining a 12-hour
cyclosporine trough level of 60–80 ng/ml [50–67 nmol/l]
(mean dose 4.7 mg/kg/d) compared to children treated with
2.5 mg/kg/d (Table 3, Online Suppl Tables 6–7).67 Limited
data suggest peak (C2) levels rather than trough (C0) levels
can be used for monitoring.68
Tacrolimus has not been studied in RCTs in children with
SSNS. Tacrolimus is widely used in North America in
children with FR and SD SSNS, because of the cosmetic side
effects of cyclosporine. There are few data to support its use,
though its efficacy would appear to be similar to that of
cyclosporine based on an observational study in SD SSNS.69
The tacrolimus dose is adjusted to maintain the 12-hour
trough levels in the range of 5–10 ng/ml [6–12 nmol/l]
initially based on data from kidney transplant studies.
The principal side-effects of cyclosporine are kidney
dysfunction, hypertension, gum hypertrophy, and hypertri-
chosis. Hypertension and kidney dysfunction are reported in
5–10% of children.49,64,66 Hypertrichosis and gum hyper-
trophy develop in 70% and 30%, respectively, in children
treated with cyclosporine for more than 1 year.64 Tacrolimus
also causes kidney dysfunction and hypertension, but
significantly less hypertrichosis; tacrolimus-associated dia-
betes mellitus has been described in children with nephrotic
syndrome.70
In children receiving cyclosporine for 12 months or
more, tubulointerstitial lesions on kidney biopsy are reported
in 30–40% of cases. This increases to 80% after 4 or more
years of treatment.71 Cyclosporine-associated arteriopathy is
uncommon. The duration of safe therapy is controversial,
with some authors suggesting that CNI therapy should be
restricted to 2 years,71 while others have suggested that longer
courses of cyclosporine can be tolerated.72
Coadministration of ketoconazole with cyclosporine in
children with SD SSNS resulted in a 48% reduction in mean
dose of cyclosporine, equivalent to a net cost saving of 38%
with no reduction in efficacy, in a nonrandomized compara-
tor study.73 This approach to therapy has been suggested in
order to help offset the costs of this drug class.
MMF
To date, all studies of mycophenolic acid prodrugs in
nephrotic syndrome have used MMF. In a small RCT, five
of 12 children treated for 1 year with MMF relapsed
compared to one of 12 treated with cyclosporine. Although
this difference was not statistically significant, the patient
numbers were too small to determine the relative efficacies of
MMF and cyclosporine (Table 3, Online Suppl Tables 4–5).74
GFR remained stable during MMF treatment but fell during
cyclosporine treatment. In a prospective study of 33 children
(26 with FR SSNS) treated with MMF for 6 months, 24
(75%) children remained in remission during therapy, with
12 remaining relapse-free for 6 months after the drug was
ceased; eight of these 12 patients continued in remission
during 18–30 months of follow-up.75 In a retrospective study
Table 3 | RCTs comparing corticosteroid-sparing agents in FR and SD SSNS
Agents
N of
RCTs
N of
patients
Risk ratio of
relapse (95% CI)
Time of outcome
(months) Conclusion
Cyclophosphamide 8 wk vs. 2 wk 1 29 0.25 (0.07, 0.92) 12 8 wk significantly more effective
Cyclophosphamide 8 wk vs. 12 wk 1 73 0.98 (0.74, 1.28) 24 No significant difference
Cyclophosphamide 8 wk vs.
chlorambucil 8 wk
1 50 1.15 (0.69, 1.94), 12 No significant difference
i.v. vs. oral cyclophosphamide 2 83 0.99 (0.76, 1.29) 12–24 No significant difference
Cyclophosphamide vs. cyclosporine 1 55 1.07 (0.48, 2.35) 9 No significant difference during therapy
Chlorambucil vs. cyclosporine 1 40 0.82 (0.44, 1.53) 6 No significant difference during therapy
i.v. cyclophosphamide vs. levamisole 1 40 1.00 (0.7, 1.43) 12 No significant difference
Mycophenolate vs. cyclosporine 1 24 5.0 (0.68, 36.66) 12 No significant difference (small numbers)
Cyclosporine 5mg/kg vs. 2.5mg/kg 1 44 Hazard ratio
0.37 (0.18, 0.79)
24 Higher dose significantly more effective
CI, confidence interval; FR, frequently relapsing; RCT, randomized controlled trial; SD, steroid-dependent; SSNS, steroid-sensitive nephrotic syndrome.
Data from Hodson et al.49
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of SD SSNS in 42 children, who were treated for at least
6 months, mean reduction in relapse rate was 3.8 per year.76
MMF was generally well tolerated, with small numbers of
children developing leucopenia and abdominal pain. In
observational studies, MMF has been used for up to
45 months and has been well tolerated.76 In most studies,
MMF has been given in a dose of 1200 mg/m2/d or about
30 mg/kg/d in two divided doses. MMF has been used with
cyclosporine in children with poorly controlled SD SSNS
and has allowed reduction in cyclosporine dose.77 Myco-
phenolate sodium may be an alternative if MMF is not
tolerated because of adverse effects, but there are no data
to support its use in nephrotic syndrome. In pediatric kidney
transplant patients on cyclosporine, a single-dose pharmaco-
kinetic study has demonstrated that 450 mg/m2 myco-
phenolate sodium and 600 mg/m2 of MMF provide similar
mycophenolic acid exposure.78 Recruitment has com-
menced for an RCT comparing MMF to cyclophosphamide
(ClinicalTrials.gov identifier NCT01092962).
Choice of First Agent for FR or SD SSNS
There are no data from RCTs to determine which
corticosteroid-sparing agent should be used as the first agent
in a child with FR or SD SSNS. In Table 4, the advantages and
disadvantages of alkylating agents, levamisole, CNIs, and
MMF are presented. This table should help in the decision-
making of the clinician and families in determining which
agent a child with FR or SD SSNS should receive as their first
corticosteroid-sparing agent.
Rituximab in SD SSNS
The place of rituximab in treatment of SD SSNS remains
to be established. A single open-labeled RCT enrolling
54 children with SD SSNS dependent on prednisone and
CNIs found that rituximab reduced the rate of relapse at
3 months significantly (18.5% and 48.1% in experimental
and control arms, respectively) and increased the prob-
ability of being free of prednisone and CNI treatment.79
These data confirm the results of case series that have
reported prolonged remissions in 80% of children following
rituximab, an anti CD20 monoclonal antibody, with
doses of 375 mg/m2 per dose given for up to four weekly
doses.80,81 Rituximab caused acute reactions, such as fever,
vomiting and diarrhea, skin rash, and bronchospasm in
about one-third of patients in one series.81 Other reported
serious side effects include Pneumocystis jiroveci pneumonia
and pulmonary fibrosis.80,82 Patient recruitment has commenced
for an RCT comparing rituximab to placebo in cyclosporine-
dependent SD SSNS (Clinicaltrials.gov identifier NCT
01268033).
Other Medications
Mizoribine is widely used as a corticosteroid-sparing agent in
Japan. A single RCT (197 patients) demonstrated that the
relapse rate (measured as the ratio of the total number of
relapses/duration of observation in the mizoribine-treated
group and placebo group) did not differ significantly between
treatment and placebo groups (relapse-rate ratio 0.81; 95%
CI 0.61–1.05)63 (Table 2).
Table 4 | Advantages and disadvantages of corticosteroid-sparing agents as first agent for use in FR or SD SSNS
Agent Advantages Disadvantages
Cyclophosphamide Prolonged remission off therapy
Inexpensive
Less effective in SD SSNS
Monitoring of blood count during therapy
Potential serious short- and long-term adverse effects
Only one course should be given
Chlorambucil Prolonged remission off therapy
Inexpensive
Less effective in SD SSNS
Monitoring of blood count during therapy
Potential serious adverse effects
Only one course should be given
Not approved for SSNS in some countries
Levamisole Few adverse effects
Generally inexpensive
Continued treatment required to maintain remission
Limited availability
Not approved for SSNS in some countries
Cyclosporine Prolonged remissions in some children with SD SSNS Continued treatment often required to maintain remission
Expensive
Nephrotoxic
Cosmetic side-effects
Tacrolimus Prolonged remissions in some children with SD SSNS Continued treatment often required to maintain remission
Expensive
Nephrotoxic
Risk of diabetes mellitus
Not approved for SSNS in some countries
Mycophenolate mofetil Prolonged remissions in some children with FR and SD SSNS
Few adverse effects
Continued treatment often required to maintain remission
Probably less effective than CNIs
Expensive
Not approved for SSNS in some countries
FR, frequently relapsing; SD, steroid-dependent; SSNS, steroid-sensitive nephrotic syndrome.
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It is recommended that azathioprine not be used as a
corticosteroid-sparing agent in FR and SD SSNS, since two
RCTs have demonstrated no significant difference in the risk
of relapse between azathioprine and placebo (RR 0.90; 95%
CI 0.59–1.38)49 (Table 2).
3.4: Indication for kidney biopsy
3.4.1: Indications for kidney biopsy in children with
SSNS are (Not Graded):
K late failure to respond following initial
response to corticosteroids;
K a high index of suspicion for a different
underlying pathology;
K decreasing kidney function in children
receiving CNIs.
RATIONALE
Kidney biopsy is indicated in children with nephrotic
syndrome who fail to respond to corticosteroids after
one or more remissions (late nonresponder) to determine
kidney pathology. There is no fixed upper age limit for
treating children with nephrotic syndrome without prior
kidney biopsy, particularly in Northern Europe and
India where 40–50% adolescents have MCD.14,83,84 How-
ever, in populations with a much higher prevalence of
FSGS and other pathologies, particularly African or African-
American populations, it is reasonable to consider biopsy
at the time of onset of nephrotic syndrome diagnosis before
treatment.85 While it is sometimes recommended that
children with SSNS should undergo annual kidney biopsy
if CNI therapy is continued beyond 2 years,71 there are
no data to determine whether the benefits of regular
biopsies exceed the harm. Biopsies should be considered in
children with deteriorating kidney function, when this
persists after CNI doses are reduced. Routine biopsies of
children with FR or SD SSNS before using corticosteroid-
sparing therapy are not indicated. Studies show that the most
important predictor for kidney survival in childhood
nephrotic syndrome is not kidney pathology, but the
achievement and maintenance of remission following any
therapy.86
3.5: Immunizations in children with SSNS
3.5.1: To reduce the risk of serious infections in
children with SSNS (Not Graded):
K Give pneumococcal vaccination to the chil-
dren.
K Give influenza vaccination annually to the
children and their household contacts.
K Defer vaccination with live vaccines until
prednisone dose is below either 1 mg/kg
daily (o20 mg/d) or 2 mg/kg on alternate
days (o40 mg on alternate days).
K Live vaccines are contraindicated in
children receiving corticosteroid-sparing
immunosuppressive agents.
K Immunize healthy household contacts with
live vaccines to minimize the risk
of transfer of infection to the immunosup-
pressed child but avoid direct expo-
sure of the child to gastrointestinal, urinary,
or respiratory secretions of vaccinated
contacts for 3–6 weeks after vacci-
nation.
K Following close contact with Varicella in-
fection, give nonimmune children on im-
munosuppressive agents varicella zoster
immune globulin, if available.
RATIONALE
Children with nephrotic syndrome are at increased risk of
invasive pneumococcal disease87 and should receive pneu-
mococcal immunization with the heptavalent conjugate
vaccine (7vPCV) and the 23-valent polysaccharide vaccine
(23vPPV) according to local recommendations for initial
immunization and repeat immunization. Adequacy of
response to the 7vPCV vaccine has not been studied in
children with nephrotic syndrome. Serological response to
23vPPV was not different in children with active nephrotic
syndrome on high-dose prednisone (60 mg/m2/d) compared
to children who received the vaccine while on low-dose
alternate day prednisone.88 In most patients, antibody levels
persisted for at least 36 months.89 Children with SSNS and
their household contacts should receive annual influenza
vaccination.90,91
Live Vaccines
Live vaccines (measles, mumps, rubella, varicella, rota-
virus) are contraindicated in children on immunosup-
pressive or cytotoxic agents90,91 and should be deferred
until:
K Prednisone dose is below 1 mg/kg/d (below 20 mg/d) or
below 2 mg/kg on alternate days (below 40 mg on alter-
nate days).
K The child has been off cytotoxic agents (cyclophos-
phamide, chlorambucil) for more than 3 months.
K The child has been off other immunosuppressive
agents (CNIs, levamisole, MMF) for more than 1 month.
Healthy siblings and household contacts of children with
impaired immunity should be vaccinated with measles,
mumps, rubella, varicella, and rotavirus vaccines (where
indicated) to prevent them from infecting children with
impaired immunity.90 However, immunosuppressed children
should avoid direct exposure to gastrointestinal, urinary, or
respiratory secretions of vaccinated contacts for 3–6 weeks
after vaccination.
Varicella Immunization
Varicella infection may lead to life-threatening disease in
children receiving immunosuppressive medications. Varicella
immunization is safe and effective in children with nephrotic
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syndrome, including children on low-dose alternate-day
prednisone.12
K Children with SSNS, who are not receiving immunosup-
pressive or cytotoxic agents other than low-dose daily or
alternate-day prednisone, should be offered varicella
immunization if nonimmune.90,91
K Families of nonimmune children with SSNS, who are
receiving immunosuppressive agents, should be asked to
contact their physician as soon as possible if the child
comes into close contact with another child with chicken
pox, or an adult with herpes zoster, so that the child can
receive zoster immune globulin (if available) within 72
hours of exposure.90
K Aciclovir or valaciclovir should be administered to
immunosuppressed children at the onset of chicken pox
lesions.
RESEARCH RECOMMENDATIONS
Further information from RCTs is required:
K To determine the relative efficacies of alkylating agents,
levamisole, MMF, CNIs in FR and SD SSNS.
K To determine the relative benefits and adverse effects of
cyclosporine and tacrolimus in FR and SD SSNS.
K To determine the additional benefits and risks of
mycophenolic acid when added to CNIs in SD SSNS.
K To determine the additional benefits and risks of
rituximab in comparison or in addition to other
corticosteroid-sparing agents in SD SSNS.
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